Trial Profile
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B) a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK; Human Genome Sciences
- 15 Nov 2023 Results of post hoc analysis pooled data from the three multicenter LTE studies (112626, 112233, 112234), presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of comprehensive analysis of infections among BEL-treated patient presented at the ACR Convergence 2023
- 13 Jul 2019 Results evaluating long term safety and tolerability including organal damage accrual published in the Rheumatology